Flupentixol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Flupentixol: From Schizophrenia to Retinal Dystrophy (Model Prediction Only)
One-Sentence Summary
Flupentixol is an antipsychotic originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia (from the knowledge graph; the Singapore licence record contains no indication text) |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Pharmacology records show that flupentixol binds dopamine D1, D2, D3 and D5 receptors. It is a thioxanthene antipsychotic whose effect in schizophrenia is understood to come mainly from dopamine receptor antagonism.
For the predicted indication, no mechanistic link is established. Inherited retinal dystrophies are genetically heterogeneous, and no known pathway connects dopamine receptor blockade to their underlying causes. The very high TxGNN score (0.9999) is a graph-based prediction and should not be read as evidence of efficacy.
Other predictions in the top 10 (all L5, all Hold):
| Rank | Predicted Indication | TxGNN Score | Comment |
|---|---|---|---|
| 2 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 99.99% | No disease-modifying relevance for dopamine antagonism; antipsychotic neurological side effects are a concern |
| 3 | Congenital disorder of glycosylation with defective fucosylation | 99.99% | Metabolic defect unrelated to receptor pharmacology |
| 4 | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99.99% | Developmental malformation; a symptomatic drug is not expected to modify it |
| 5 | Hydranencephaly | 99.99% | Structural brain anomaly with no pharmacological rationale |
| 6 | Myopia, X-linked | 99.99% | Retinal dopamine influences eye growth, but antagonism would be expected to be unfavourable |
| 7 | Syndromic myopia | 99.99% | Same limitation as above |
| 8 | Myopia 26, X-linked, female-limited | 99.98% | Same limitation as above |
| 9 | Atypical glycine encephalopathy | 99.98% | No known action on glycine metabolism |
| 10 | Distal 17p13.3 microdeletion syndrome | 96.01% | Genetic deletion that a receptor antagonist would not correct |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN00913P | DEANXIT TABLET (H. Lundbeck A/S) | Film-coated tablet (oral) | Not stated in the licence record |
Safety Considerations
- Drug Interactions: The interaction search completed, but it returned only pharmacological target records (dopamine D1, D2, D3 and D5 receptors), not drug–drug interactions. No interacting drugs are listed.
- Class-related caution: Antipsychotics can cause extrapyramidal and other neurological adverse effects. This would need careful consideration in any neurological population, such as patients with Charcot-Marie-Tooth disease.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The predictions rest only on model scores. There are no clinical trials or publications, and no plausible mechanistic link between dopamine receptor antagonism and any of the predicted conditions. The Singapore licence record also lacks approved indication and safety text.
To proceed, the following is needed:
- Retrieval of the package insert (warnings, contraindications, approved indications) from the HSA website
- Detailed mechanism of action data from DrugBank
- Preclinical or mechanistic evidence for a link to retinal dystrophy, or a literature and trial search to confirm none exists
- A review of the safety profile for the proposed target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.